Hypoglycemia — defined as a blood glucose level below 70 mg/dL (3.9 mmol/L) — is one of the most common acute complications in people living with diabetes. While many cases are triggered by medication overtitration, missed meals, or unplanned physical activity, a deeper biological driver often goes unrecognized: hormonal imbalance. The endocrine system orchestrates a delicate glucose regulatory network, and when any node in this network malfunctions, the risk of severe hypoglycemia rises sharply.

For decades, diabetes management focused almost exclusively on insulin dose adjustment and carbohydrate counting. Yet a growing body of evidence highlights that disruptions in the counter‑regulatory hormone axis — including cortisol, growth hormone, glucagon, and catecholamines — are central to hypoglycemia pathophysiology, especially in patients with long‑standing diabetes or coexisting endocrine disorders. Recognizing these hormonal influences transforms hypoglycemia from a purely iatrogenic problem to a systemic endocrine challenge that demands comprehensive evaluation and tailored intervention.

The Hormonal Symphony of Blood Glucose Control

Maintaining blood glucose within a narrow range is a whole‑body effort requiring precise coordination among several hormones. Each hormone has a specific role, and in diabetes, both the primary and secondary hormonal responses become disrupted.

Insulin – The Primary Glucose‑Lowering Hormone

Insulin, secreted by the pancreatic beta‑cells, drives glucose into peripheral tissues (muscle, fat, liver) and suppresses hepatic glucose production. In type 1 diabetes, insulin secretion is nearly absent; in type 2 diabetes, insulin resistance coexists with progressive beta‑cell dysfunction. Exogenous insulin or insulin‑secretagogues can cause hypoglycemia when doses exceed physiological need or when the insulin‑to‑glucagon ratio becomes unbalanced.

Glucagon – The First Line of Defence Against Hypoglycemia

Glucagon, released from alpha‑cells, acts primarily on the liver to stimulate glycogenolysis and gluconeogenesis. In healthy individuals, falling blood glucose triggers a rapid glucagon surge. However, many people with diabetes — particularly those with type 1 and advanced type 2 — lose this glucagon response within a few years of diagnosis. This “glucagon deficiency in hypoglycemia” leaves patients without the most immediate counter‑regulatory mechanism, making even mild insulin excess dangerous.

Counter‑Regulatory Hormones: The Second and Third Lines

When glucagon fails to restore euglycemia, the body recruits other counter‑regulatory hormones:

  • Epinephrine (adrenaline): Released from the adrenal medulla, epinephrine increases hepatic glucose output, limits insulin secretion, and mobilises free fatty acids. It also triggers autonomic symptoms (tremor, palpitations, sweating) that alert the patient to hypoglycemia. Loss of epinephrine response, known as “hypoglycemia‑associated autonomic failure” (HAAF), is common in recurrent hypoglycemia and intensifies the risk of severe episodes.
  • Norepinephrine: A sympathetic neurotransmitter that contributes to vasoconstriction and metabolic responses, though its role in glucose counter‑regulation is less dominant than epinephrine’s.
  • Cortisol: The primary stress hormone from the adrenal cortex. Cortisol promotes gluconeogenesis and reduces peripheral glucose utilisation. Its effects develop over hours rather than minutes, making it more important during prolonged fasting or stress.
  • Growth hormone (GH): GH antagonises insulin action and stimulates lipolysis, thereby sparing glucose. Like cortisol, its counter‑regulatory effects are slower and more sustained.

In diabetes, the interplay of these hormones is often altered. For example, repeated hypoglycemic episodes can blunt both the glucagon and epinephrine responses — a phenomenon known as “hypoglycemia unawareness” — which dramatically increases the risk of future severe events.

Hormonal Imbalances That Raise Hypoglycemia Risk

Several endocrine disorders and hormonal disturbances can independently or synergistically intensify hypoglycemia susceptibility in people with diabetes.

Adrenal Insufficiency

Adrenal insufficiency (primary, secondary, or tertiary) reduces cortisol production. Since cortisol is essential for gluconeogenesis and maintaining baseline glucose production, even mild deficiency can lower the threshold for hypoglycemia. In diabetic patients, the combination of exogenous insulin and impaired cortisol reserve creates a precarious state. Clinical clues include unexplained hypoglycemia, fatigue, hyperpigmentation (in primary AI), and electrolyte abnormalities. Any diabetic patient with recurrent unexplained hypoglycemia should undergo a cosyntropin stimulation test to rule out adrenal insufficiency.

Management involves hormone replacement therapy (typically hydrocortisone or prednisone) with stress‑dose protocols for illness or surgery. In patients with type 1 diabetes, glucocorticoid replacement may increase insulin requirements, so close glucose monitoring and insulin dose adjustments are required. The Endocrine Society guidelines recommend a multidisciplinary approach for these complex cases.

Growth Hormone Deficiency

Growth hormone (GH) promotes lipolysis and reduces glucose utilisation. Adults with GH deficiency (often from pituitary disorders) have increased insulin sensitivity and a higher risk of fasting hypoglycemia. In diabetic patients, GH deficiency can unmask or worsen hypoglycemia, especially if they are on insulin or sulfonylureas. Diagnosis requires dynamic testing (e.g., insulin tolerance test or glucagon stimulation test). Replacement therapy with recombinant GH can improve metabolic stability, but careful dose titration is essential to avoid hyperglycemia.

Thyroid Disorders

Both hyperthyroidism and hypothyroidism affect glucose metabolism in ways that influence hypoglycemia risk:

  • Hyperthyroidism: Excess thyroid hormone accelerates glucose absorption, increases gluconeogenesis, and raises basal metabolic rate. In diabetes, this often results in higher insulin requirements. However, rapid swings between hyperglycemia and hypoglycemia can occur, particularly when thyroid function normalises after treatment (e.g., carbimazole or radioiodine). Careful monitoring of both glucose and thyroid function is necessary during dose adjustments.
  • Hypothyroidism: Reduced thyroid hormone slows metabolism and gastrointestinal glucose absorption, leading to decreased insulin requirements. If insulin doses are not reduced accordingly, hypoglycemia becomes common. Additionally, hypothyroidism can impair hepatic glycogenolysis, blunting counter‑regulation. Levothyroxine replacement should be gradual, and insulin doses must be reassessed frequently.

Diabetes guidelines now recommend annual thyroid‑stimulating hormone (TSH) screening in all patients with diabetes given the high prevalence of comorbid thyroid dysfunction.

Sex Hormone Imbalances

Emerging research points to the role of estrogens and androgens in glucose homeostasis. Estradiol enhances insulin sensitivity, while testosterone has variable effects. In women with diabetes, menopause‑related decline in estrogen can worsen insulin resistance and increase hypoglycemia risk when insulin doses are not adjusted. Conversely, polycystic ovary syndrome (PCOS) — characterised by hyperandrogenism and insulin resistance — creates a state of fluctuating glucose control that predisposes to both hyper‑ and hypoglycemia.

For men, low testosterone (hypogonadism) is associated with increased body fat and insulin resistance, but its direct link to hypoglycemia is less clear. Testosterone replacement therapy may improve insulin sensitivity but must be monitored to avoid sudden changes in glucose balance.

Glucagon Excess or Deficiency Syndromes

While glucagon deficiency is classically seen in long‑standing type 1 diabetes, glucagon excess can occur in certain pancreatic neuroendocrine tumors (glucagonomas). Glucagonomas produce hyperglycemia (diabetes) but interestingly, the metabolic dysregulation can include periods of severe hypoglycemia due to reactive hyperinsulinemia or altered hepatic response. Such cases are rare but illustrate the profound impact of glucagon alone.

In diabetic patients, alpha‑cell dysfunction is common. Studies using islet imaging show that alpha‑cells in type 1 diabetes lose their ability to sense glucose and secrete glucagon appropriately. Restoring endogenous glucagon response is an area of active research, including the development of “smart” insulin formulations and glucagon co‑agonists.

Clinical Implications: Integrating Hormonal Assessment into Diabetes Care

Recognizing the role of hormonal imbalances in hypoglycemia is not merely academic — it has direct therapeutic consequences. The traditional approach of adjusting insulin alone often fails when an underlying endocrine disorder remains uncorrected.

Diagnostic Evaluation for Unexplained Hypoglycemia

Any patient with diabetes who experiences repeated or severe hypoglycemia should undergo a targeted workup:

  • Detailed history: frequency of events, timing (fasting vs. postprandial), precipitating factors, presence of autonomic symptoms, and history of other endocrine conditions.
  • Laboratory testing: morning cortisol (preferably after ACTH stimulation), TSH, free thyroxine (FT4), IGF‑1 (screening for GH deficiency), and in suspicious cases, plasma metanephrines for pheochromocytoma.
  • Continuous glucose monitoring (CGM): reveals patterns of hypoglycemia and can identify periods of reduced glucose variability that may point to hormonal blunting.
  • Imaging: when pituitary or adrenal structural lesions are suspected (e.g., after abnormal lab results), CT or MRI of the sella or adrenal glands may be indicated.

Management Strategies in Patients with Hormonal Imbalances

  1. Hormone replacement therapy: For adrenal insufficiency, stress‑dose glucocorticoids and daily replacement; for GH deficiency, recombinant GH with dose titration based on IGF‑1 and clinical response; for hypothyroidism, levothyroxine aimed at normal TSH.
  2. Insulin dose adjustments: When cortisol or GH is replaced, insulin sensitivity often improves, necessitating lower doses. Conversely, during acute illness (stress), doses may need to increase. A written sick‑day plan is essential.
  3. Dietary modifications: Frequent smaller meals with complex carbohydrates can buffer against fasting hypoglycemia in GH‑ or cortisol‑deficient patients. In hyperthyroidism, consistent carbohydrate intake is important to avoid overcorrection with insulin.
  4. Technology‑driven insights: CGM with alarms, automated insulin delivery systems (e.g., hybrid closed‑loop), and smart insulin pens can help detect and prevent hypoglycemia, especially in patients with blunted counter‑regulatory responses. The American Diabetes Association now advocates for CGM use in all patients at high risk for hypoglycemia.
  5. Education for hypoglycemia unawareness: Structured training programs (e.g., Dose Adjustment for Normal Eating, or DAFNE) that teach patients to recognise early symptoms, avoid over‑treatment, and use glucagon pens appropriately.

Special Considerations for Hospitalised Patients

Hospitalised diabetic patients with endocrine comorbidities require even closer monitoring. Surgery, infections, and fasting for procedures can precipitate hypoglycemia. Peri‑operative management should include baseline hormonal levels, stress‑dose steroids if known adrenal insufficiency, and frequent point‑of‑care glucose monitoring. The National Institute of Diabetes and Digestive and Kidney Diseases provides guidelines on inpatient diabetes care that incorporate hormonal factors.

Conclusion: A Call for Endocrine‑Aware Diabetes Care

Hormonal imbalances are far more than a theoretical contributor to hypoglycemia — they are a clinical reality that affects countless patients with diabetes. Adrenal insufficiency, growth hormone deficiency, thyroid disorders, and sex hormone changes each alter the delicate architecture of glucose homeostasis. When these conditions go undiagnosed or untreated, hypoglycemia becomes a persistent and dangerous companion, eroding quality of life and increasing the risk of morbidity and mortality.

The modern diabetes care team must expand its diagnostic lens. Every unexplained hypoglycemic event should prompt a thoughtful endocrine workup. Tailoring insulin regimens, integrating advanced glucose monitoring technology, and correcting hormonal deficits can dramatically reduce hypoglycemia burden. As research continues to uncover the intricate communication between pancreatic, pituitary, adrenal, and thyroid hormones, clinicians who embrace this complexity will be best positioned to offer their patients not just metabolic control but true metabolic safety.

By bridging the gap between endocrinology and diabetology, we can move beyond simply treating the numbers and instead treat the whole hormonal system that keeps those numbers in balance.